After spending $87M promoting Lipitor in the U.S. even after its patent expired, Pfizer (PFE) is...

|About: Pfizer Inc. (PFE)|By:, SA News Editor

After spending $87M promoting Lipitor in the U.S. even after its patent expired, Pfizer (PFE) is giving up on its former cash cow for good because more generic versions will soon be going on sale. For its next act, PFE is trying to reshape itself into a leaner company, but analysts say it might still be too big for the cost-cutting and launches of new drugs like tofacitinib to have a significant effect.